Guardant Health GH 深 滬
已收盤 05-08 16:00:00 美东时间
95.70
+3.440
+3.73%
華盛通- 最 高98.50
- 今 開96.57
- 成交量 318.68万股
- 最 低 89.0708
- 昨 收 92.26
- 總市值 126.87亿
- 52周最高 120.74
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 36.36
- 委 比 -82.08%
- 總股本 1.33亿
- 歷史最高 181.07
- 量 比 1.99
- 振 幅 10.22%
- 歷史最低 15.81
- 每 手 1
- 風險率 24.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guardant Health CMO resigns
Guardant Health Chief Medical Officer Craig Eagle has resigned from the company, effective Friday. An SEC filing did not indicate the reasons for his departure, nor who his replacement is. Eagle prev...
05-08 23:49
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson
U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson May 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, McDonald's and McKesson on Friday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Berenb
05-08 15:12
财报速睇 | Guardant Health 2026财年Q1营收3.02亿美元，同比增长48.3%；归母净利润亏损1.12亿美元，同比亏损扩大17.8%
华盛资讯5月8日讯，Guardant Health公布2026财年Q1业绩，公司Q1营收3.02亿美元，同比增长48.3%，归母净利润亏损1.12亿美元，同比亏损扩大17.8%。
05-08 09:22
财报速睇 | Guardant Health 2026财年Q1营收3.02亿美元，同比增长48.3%；归母净利润亏损1.12亿美元，同比亏损扩大17.8%
华盛资讯5月8日讯，Guardant Health公布2026财年Q1业绩，公司Q1营收3.02亿美元，同比增长48.3%，归母净利润亏损1.12亿美元，同比亏损扩大17.8%。
05-08 06:02
Guardant Health shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY2026 sales guidance above estimates.
Guardant Health shares are trading higher after the company reported better-tha...
05-08 05:20
Guardant Health Raises FY2026 Sales Guidance from $1.250B-$1.280B to $1.300B-$1.320B vs $1.271B Est
2026 GuidanceGuardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to full year 2025. This compares to the prior range of $1.25 to
05-08 04:08
William Blair updates conviction stock list
William Blair updated its 2026 conviction stock list, swapping in three new names. Additions Somnigroup International Inc. (SGI): Added to the Consumer sector by analyst Phillip Blee. The rationale is...
05-04 18:37
Pfizer, Arvinas breast cancer therapy approved by the FDA
The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand name Veppanu. Accordingly, the once-daily o...
05-02 00:47
Guardant Health And Nuvalent Enter Strategic Collaboration For The Development And Potential Commercialization Of Nuvalent's Oncology Pipeline Using The Guardant Infinity Platform's Tissue And Liquid Tools
The collaboration reflects the growing importance of precision diagnostics in oncology drug development, where biomarker-driven approaches are increasingly essential for identifying appropriate patient populations,
04-30 20:12
Why Is Guardant Health Stock Falling On Tuesday?
FDA highlights concerns over camizestrant data, questioning PFS relevance, OS maturity, and benefit-risk profile in SERENA-6 trial.
04-29 02:30
